<SEC-DOCUMENT>0001193125-17-339920.txt : 20171113
<SEC-HEADER>0001193125-17-339920.hdr.sgml : 20171110
<ACCEPTANCE-DATETIME>20171113081856
ACCESSION NUMBER:		0001193125-17-339920
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20171113
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171113
DATE AS OF CHANGE:		20171113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		171193273

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d475110d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;13, 2017 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-31791</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">04-3562325</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678) <FONT STYLE="white-space:nowrap">620-3186</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:pmingliu"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;<FONT STYLE="font-family:pmingliu"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7 &#150; REGULATION FD </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;13, 2017, Galectin Therapeutics&nbsp;Inc.
(the &#147;Company) issued the press release attached hereto as Exhibit 99.1.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this report is being furnished pursuant
to this Item&nbsp;7.01 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, and it shall not be
deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND EXHIBITS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d475110dex991.htm">Press release </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: November&nbsp;13, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter G. Traber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter G. Traber, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d475110dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>


<IMG SRC="g475110g1110233502826.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">


<IMG SRC="g475110g1110233502732.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combination Immunotherapy of Pembrolizumab with the
<FONT STYLE="white-space:nowrap">Galectin-3</FONT> Inhibitor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> Shows Promising Early Results in Treatment of
Advanced Melanoma </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>from a Phase 1b Clinical Trial </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The objective response rate in advanced melanoma was 62.5% (five of eight subjects) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NORCROSS, Ga. (November 13, 2017)</B> &#150; <B>Galectin Therapeutics Inc. (NASDAQ: GALT</B>), the leading developer of therapeutics that target galectin
proteins, and Providence Cancer Institute today announced the presentation of preclinical and early clinical data from an investigator-initiated Phase 1 clinical trial of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> used in combination with pembrolizumab (KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Data of two complimentary abstracts were presented
Nov. 11, 2017 at the Annual Meeting of the Society for Cancer Immunotherapy in National Harbor, Md., by William L. Redmond, Ph.D., Earle A. Chiles Research Institute, a division of Providence Cancer Institute (data posted). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Three patients in cohort 2 (4 mg/kg <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02)</FONT></FONT> have now been completed to add
to the six patients in dose cohort 1 (2 mg/kg <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02).</FONT></FONT> One patient in the first cohort had head and neck cancer, while the remaining eight patients had advanced
melanoma. Five patients with advanced melanoma had objective responses after five courses of every three-week therapy, with three partial responses and two complete responses. All the patients in the second cohort had an objective response. Please
refer to the posted data to review additional information on the patients who responded. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475110g1110233502919.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Waterfall plot of best clinical response (RECIST 1.1) post-treatment. Dotted line at <FONT
STYLE="white-space:nowrap">-30%</FONT> change from </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>baseline indicates the RECIST 1.1 threshold for definition of partial response.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In addition to the encouraging clinical responses seen in this study, we are making progress on identifying immunological markers that may
predict clinical responses to the combination therapy,&#148; said Redmond, associate member, Laboratory of Cancer Immunotherapy, and director, Immune Monitoring Laboratory. &#147;In this regard, we have shown that clinical responders to the
combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> and pembrolizumab may have reduced myeloid-derived suppressor cells following treatment.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Providence Cancer Institute translational medicine team conducted two phase 1 clinical trials, initiated under direction of principal investigator Brendan
D. Curti, M.D., director, Genitourinary Oncology Research and Immunotherapy Clinical Program, and <FONT STYLE="white-space:nowrap">co-director,</FONT> Melanoma Program. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> was also combined in an <FONT
STYLE="white-space:nowrap">investigator-led</FONT> trial with ipilimumab (Yervoy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced melanoma
(<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://clinicaltrials.gov/ct2/show/NCT02117362?term=GR-MD-02&amp;rank=6</FONT></FONT></U>). Seven subjects treated with the lowest two dose cohorts of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> (1 and 2 mg/kg) have been completed with no safety signals identified due to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02.</FONT></FONT>
In these low dose initial cohorts, there were no notable changes in the peripheral immune signature. Due to changes in the standard of care for metastatic melanoma (i.e., approval of
KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), recruitment has been slowed significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged by these early
safety and efficacy results and look forward to further data on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> used in combination with pembrolizumab in patients with metastatic melanoma or head and neck
cancer,&#148; said Curti. &#147;An objective response rate of five out of eight patients (62.5%) with advanced melanoma, including two complete responses, is very encouraging and compares favorably with the known response rates with pembrolizumab
alone (ORR of ~ 33%). We have begun enrolling cohort 3 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GR-MD-02</FONT></FONT> 8 mg/kg), which will include at least 10 patients with melanoma to provide a larger group of patients to
evaluate. We hope to report additional data in <FONT STYLE="white-space:nowrap">mid-2018</FONT> when we anticipate a decision on progressing to phase 2. This decision will be based on the response rate of the combination with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> as compared to historical response rates to pembrolizumab alone.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Galectin Therapeutics is delighted with our collaboration and the excellent work by Providence Cancer Institute,&#148; said Peter Traber, M.D., CEO and
CMO of Galectin Therapeutics. &#147;It is known that <FONT STYLE="white-space:nowrap">galectin-3</FONT> produced by tumors is important in avoidance of immune recognition by cancer cells, and we are gratified by the large body of <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> work and these early clinical trials that may support the combination of our <FONT STYLE="white-space:nowrap">galectin-3</FONT> inhibitor,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02,</FONT></FONT> with immune checkpoint inhibitors. It is important to note that not all <FONT STYLE="white-space:nowrap">galectin-3</FONT> inhibitors may be effective, as we
have shown that a previous drug <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GM-CT-01</FONT></FONT> (DAVANAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) had no effect in the same
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> models. Finally, the use of combination immunotherapy with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> is covered by a joint Galectin-Providence U.S.
patent with exclusive rights granted to Galectin.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> is a complex carbohydrate drug that targets <FONT
STYLE="white-space:nowrap">galectin-3,</FONT> a critical protein in the pathogenesis of fatty liver disease and fibrosis. <FONT STYLE="white-space:nowrap">Galectin-3</FONT> plays a major role in diseases that involve scarring of organs including
fibrotic disorders of the liver, lung, kidney, heart and vascular system. The drug binds to galectin proteins and disrupts their function. Preclinical data in animals have shown that
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> has robust treatment effects in reversing liver fibrosis and cirrhosis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics is
developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage
extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and
commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Earle A. Chiles Research Institute, a division of Providence Cancer Institute, at the Robert W. Franz
Cancer Center, in Portland, Ore. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Providence Cancer Institute, a part of Providence Health&nbsp;&amp; Services, offers the latest in cancer services,
including diagnostic, treatment, prevention, education, support and internationally-renowned research. The Earle A. Chiles Research Institute, a division of Providence Cancer Institute, is a world-class research facility located within the Robert W.
Franz Cancer Center. The Institute&#146;s main area of investigation is cancer immunotherapy, a specialized field of study focused on triggering the immune system to fight cancer. Visit <U>www.chilesresearch.org</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forwarding Looking Statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. These statements relate to future events or future financial performance, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on Galectin management&#146;s current
expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin&#146;s clinical trials will lead
to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that Galectin&#146;s lead compounds will be successful in connection with cancer immunotherapy. Factors that could cause actual performance to
differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GR-MD-02</FONT></FONT> or any of its other drugs in development; the Company&#146;s current clinical trial in fibrotic liver disease and any future clinical studies may not produce positive
results in a timely fashion, if at all, and could prove time consuming and costly; plans regarding development, approval and marketing of any of Galectin&#146;s drugs are subject to change at any time based on the changing needs of the Company as
determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further
develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a
discussion of additional factors impacting Galectin&#146;s business, see the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, and subsequent filings with the SEC. You should
not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Galectin Therapeutics </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leigh Minnier </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GregoryFCA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>leigh@gregoryfca.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">610-228-2108</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Providence Health&nbsp;&amp; Services </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jean Powell Marks </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Jean.marks@providence.org </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">503-215-6433</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g475110g1110233502732.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475110g1110233502732.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& /(# 2(  A$! Q$!_\0
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M*/\ -_NG@_SKR%F%255.3LKGM3RZE"C)15Y6W.V%]=)XPN+1Y2;8VWF1QD#
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MXLX!LFEC$;.LA.0,=1\@_&N:^)5W#=I)9I>I!=Z7 -2MU+8+W"MF-?R5^/\
M:6MC(]#EEC@C:2:1(XUZL[8 _&H8-1LKJ3R[>\MY7QG;'*K'\@:HQWUKKWA%
M;]%62VO+/S0K $89<X->7:8MEJ_@;P9HFG*(/$&V"X@N#$8C''&P,KJY W?+
MD8!.<^G- 'L,][:6I47%S#"6Z>9(%S^=2JZN@=&#(PR&!R"*XSXFPQ2Z!IQD
MB1\:O9 ;E!ZS+FNT  4   #@ 4 4SJ^F#KJ-IQ_TW7_&K:.DB*Z,K(PRK*<@
MBO,M)N[72]4\<N=#EO5342^(K=67_4IP2?S/!ZUZ-86<&GV$%I:H([>% D:
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g475110g1110233502826.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475110g1110233502826.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" 24# 2(  A$! Q$!_\0
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E>>AI.WX444Q"T444 %%%% "F@=***  @8Z4G>BB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g475110g1110233502919.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475110g1110233502919.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "2 0(# 2(  A$! Q$!_\0
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M-6=BB+]__P!,_P!:/W__ $S_ %J6B@"+]_\ ],_UH_?_ /3/]:EHH B_?_\
M3/\ 6C]__P!,_P!:EHH B_?_ /3/]:/W_P#TS_6I:* (OW__ $S_ %H_?_\
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M*/.B_P">J?\ ?0H ;Y(_OR?]]FCR1_?D_P"^S3O.B_YZI_WT*/.B_P">J?\
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MM%$LX#RMO4,(S&) "0&VGD9&#0!I*!M' Z>E+M'H/RJ,/* !Y)_[Z%'F2?\
M/$_]]"@"3:/0?E1M'H/RJ/S)/^>)_P"^A1YDG_/$_P#?0H DVCT'Y4;1Z#\J
MC\R3_GB?^^A1YDG_ #Q/_?0H DVCT'Y4;1Z#\JC\R3_GB?\ OH4>9)_SQ/\
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M7EH\"^)?^?%/^_Z?XUUX*I",7S.QS8N$Y27*KG;?#< ^"+4X',T__HUJZ6\
M^PS\#_5MV]JP_!>FW^B>%[>PO;<+<(\C,%D!'S.S#GZ$5MW'G2VTL:PG+(0,
ML/2O/GJW8[J>EKGS..E>N?!S_D7-3/\ U$6_]%1UQY^&OBD$C[%"<'J+A>:]
M"^'&@:GX=TB]M=2MUCDFO&F7;(&^4H@[>ZFO/PM.<9WDNA]AQ!C,/7PT8TII
MOFZ/R9V5%%%=Y\>+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
